

1 Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine
2 platforms

3

4 Yannic Bartsch¹, Xin Tong¹, Jaweon Kang¹, María José Avendaño², Eileen F. Serrano², Tamara
5 García-Salum^{2,3}, Catalina Pardo-Roa^{2,3}, Arnoldo Riquelme^{3,4,4}, Rafael A. Medina^{2,3,6} and Galit
6 Alter

7

8 ¹ Ragon Institute of MGH, MIT, and Harvard; Cambridge, MA, USA

9 ²Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia
10 Universidad Católica de Chile, Santiago, Chile

11 ³Advanced Interdisciplinary Rehabilitation Register (AIRR) – COVID-19 Working Group, Faculty
12 of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

13 ⁴Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile,
14 Santiago, Chile

15 ⁵Department of Health Sciences, Faculty of Medicine, Pontificia Universidad Católica de Chile,
16 Santiago, Chile

17 ⁶Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

18

19

20 # correspondence: galter@mgh.harvard.edu

21 **Abstract**

22 Despite the dramatic spread of Omicron globally, even among highly vaccinated populations,
23 death rates have not increased concomitantly. These data argue that alternative immune
24 mechanisms, beyond neutralization, may continue to confer protection against severe disease.
25 Beyond their ability to bind and block infection, antibodies contribute to control and clearance
26 of multiple infections via their ability to direct antiviral immunity via Fc-effector mechanisms.
27 Thus, here we probed the ability of vaccine induced antibodies, across three COVID-19 vaccines,
28 to drive Fc-effector activity against Omicron. Despite the significant loss of IgM, IgA and IgG
29 binding to the Omicron Receptor Binding Domain (RBD) across BNT162b2, mRNA-1273, and
30 CoronaVac vaccines, stable isotype binding was observed across all of these vaccines to the
31 Omicron Spike. Compromised RBD binding IgG was accompanied by a significant loss of cross
32 RBD-specific antibody Fc γ -receptor binding by the CoronaVac vaccine, but preservation of RBD-
33 specific Fc γ R2a and Fc γ 3a binding across the mRNA vaccines. Conversely, Spike-specific
34 antibodies exhibited persistent binding to Fc γ -receptors, across all three vaccines, albeit higher
35 binding was observed with the mRNA vaccines, marked by a selective preservation of Fc γ R2a and
36 Fc γ 3a binding antibodies. Thus, despite the significant to near complete loss of Omicron
37 neutralization across several vaccine platforms against Omicron, vaccine induced Spike-specific
38 antibodies continue to recognize the virus and recruit Fc-receptors pointing to a persistent
39 capacity for extra-neutralizing antibodies to contribute Omicron disease attenuation.

40 Introduction

41 Antibodies represent the primary correlate of immunity following immunization with
42 nearly all licensed vaccines (1), providing protection either via direct blockade of infection or via
43 their ability to leverage the immune system to eliminate pathogens, should the pathogens breach
44 the portal of entry (2). Emerging data from SARS-CoV-2 Phase3 vaccine studies clearly
45 demonstrate a critical association between neutralizing and binding antibodies and protection
46 against severe COVID-19 infection(3). Yet, the emergence of SARS-CoV-2 variants of concern
47 (VOC), including the Omicron variants, which evade neutralizing antibodies, has led to increased
48 breakthrough infections globally among vaccinated individuals. Thus far, despite this striking rise
49 in breakthrough infections, a concomitant rise in severe disease and death has not been
50 observed, suggesting that vaccine mediated protection may still persist in the setting of a loss of
51 neutralizing antibody activity, pointing to a potential critical role for alternative vaccine induced
52 immune responses as critical modulators of disease severity, the ultimate goal of protection.

53 Beyond blockade of infection, cellular immune responses can directly or indirectly
54 contribute to protection against severe disease. T cells may directly recognize and eliminate
55 infected cells (4). In addition, binding antibodies with the capability of interacting with Fc-
56 receptors (FcRs), found on immune cells, can leverage the antiviral activity of the innate immune
57 system (5-9). This drives rapid opsonophagocytic clearance, infected cell cytotoxicity, or pro/anti-
58 inflammatory mediators, etc. each of which have been linked to protection against several
59 viruses including Influenza(10, 11), Ebola virus (12, 13), HIV (14), and most recently against SARS-
60 CoV2 (6-8). However, whether Fc-activity persists to provide protection against Omicron, remains
61 unclear. Thus, here we examined whether persistent Fc-activity could partially explain persistent
62 protection against death following Omicron infection. Here we show diminished antibody isotype
63 binding to the Omicron RBD across vaccine platforms, but persistence of robust Fc-activity to the
64 Omicron Spike, which likely contributes to rapidly control and clear viral infection, thereby
65 continuing to attenuate disease severity.

66 **Results**

67 **Loss of Omicron RBD recognition across vaccine induced immunity**

68 Despite the significant loss of vaccine induced neutralization against the novel Omicron
69 VOC, persistence of vaccine induced antibody binding may continue to confer protection against
70 disease via additional extra-neutralizing antibody functions that have been linked to natural
71 resolution of infection and vaccination (6-8). Thus, we probed the persistence of vaccine induced
72 antibody isotype binding to the recombinant receptor binding domain (RBD) across VOCs of the
73 SARS-CoV-2 Spike antigen (Figure 1A). Persistence of RBD recognition was compared using
74 plasma samples from 3 vaccine platforms, including the Moderna mRNA-1273(15),
75 Pfizer/BioNtech BNT162b2(16), and Sinovac CoronaVac (17), all profiled at peak immunogenicity
76 (see methods).

77 Comparable IgM responses were observed across all vaccine platforms to the RBD from
78 D614G (WT), Alpha (B.1.117), Beta (B.1.351), and Delta (B.1.617.2), with a significant loss of
79 Omicron (B.1.529) recognition by all three platforms (**Figure 1A**). mRNA vaccines induced stronger
80 IgA RBD-specific cross-VOC responses, that were compromised, but not completely lost for
81 Omicron. Moderate IgA responses were observed across RBD VOCs following CoronaVac
82 vaccination, that recognized the Beta and Omicron variants to a lesser degree. Robust IgG
83 responses were observed for mRNA vaccines, that were relatively stable across VOC RBDs,
84 including a decrease, but not complete loss of recognition of the Omicron RBD. As expected,
85 CoronaVac induced lower IgG responses across VOC RBDs, that also exhibited diminished binding
86 to the Omicron RBD. These data point to the persistent, albeit lower, recognition of the Omicron
87 RBD across isotypes by specific vaccine platforms.

88

89 **Persistent recognition of Omicron Spike across vaccine platforms**

90 While most neutralizing antibodies, that block viral infection, target the Spike antigen on
91 or proximal to the RBD (18), Fc-functional antibodies that drive clearance or killing of virus or
92 infected cells can target the whole surface of the Spike antigen. Thus, we next profiled isotype
93 recognition across Spike VOCs (**Figure 1B**). All vaccines induced Spike-specific IgM responses
94 across most VOCs and exhibited attenuated but not significantly reduced binding to the Omicron

95 Spike. Cross-Spike VOC IgA responses were most robustly induced by the BNT162b2 and mRNA-
96 1273 vaccines, but exhibited a partial decline in recognition of the Omicron Spike. Conversely,
97 the CoronaVac vaccine elicited lower IgA responses across Spike VOCs that were completely
98 preserved to Omicron. Moreover, BNT162b2 and mRNA-1273 mRNA vaccines induced the
99 highest levels of cross-Spike VOC IgG binding, which exhibited only a moderate loss of recognition
100 of the Omicron Spike. Interestingly, despite the lower overall IgG titers induced by the CoronaVac
101 vaccine, IgG responses recognized the Omicron spike identically to the wildtype spike, pointing
102 to robust preservation of Spike IgG immunity across the 3 vaccine platforms.

103

104 **Variable Omicron-specific Fc-receptor binding activity across vaccine platforms**

105 The ability of antibodies to leverage Fc-effector functions depends on their ability to
106 interact with Fc-receptors (FcR) found on all immune cells (19). Thus, we profiled the ability of
107 vaccine induced RBD and Spike-specific antibodies to interact with the four low affinity FcγRs
108 found in humans, known to regulate and drive antibody effector functions (20). mRNA vaccines
109 induced robust cross-VOC RBD-specific FcγR binding antibodies but exhibited a near complete
110 loss of inhibitory FcγR2b and neutrophil specific FcγR3b binding, while preserving detectable
111 opsonophagocytic FcγR2a and cytotoxic FcγR3a binding to the Omicron RBD (**Figure 2A**).
112 Conversely, Spike-specific FcR binding persisted more robustly to Omicron (**Figure 2B**).
113 CoronaVac induced intermediate levels of RBD-specific FcγR binding antibodies across VOCs, but
114 exhibited a near complete loss of Omicron RBD-specific FcγR binding, despite the ability to bind
115 to RBD (**Figure 1A**). These data point to qualitative differences in antibody Fc-binding capabilities
116 that are not always linked to antibody titers. Conversely, although CoronaVac induced lower
117 overall IgG levels of Spike-specific antibodies, which recognized the Omicron Spike comparably
118 to the wildtype antigen (**Figure 1B**), CoronaVac Spike antibodies exhibited a more profound
119 decline in Omicron-specific FcγR-binding (**Figure 2A**). However, a common pattern of Omicron
120 Spike-specific FcγR-binding loss was observed across the three platforms, marked by a selective
121 persistence of higher opsonophagocytic FcγR2a and cytotoxic FcγR3a receptor binding, and a
122 sharper decline of inhibitory FcγR2b and neutrophil-activating FcγR3b binding. Thus, despite the
123 significant complete loss of Omicron RBD-specific FcγR binding antibodies, the persistence of

124 robust levels of Omicron Spike-specific Fc γ R2a and cytotoxic Fc γ R3a binding antibodies likely may
125 continue to recognize, control, and clear the virus following transmission thereby attenuating
126 disease despite increases in transmission.

127 Discussion

128 As SARS-CoV-2 continues to evolve as it adapts to its new host, the virus has acquired a
129 progressive collection mutations preferentially within the S1 domain of the Spike antigen, within
130 or proximal to the receptor binding domain (RBD), aimed at enhancing Spike binding to the
131 angiotensin-converting enzyme 2 (ACE2) receptor (21). Because many of the most potent
132 neutralizing antibodies bind to the RBD, aimed at interfering or blocking interactions with ACE2,
133 both vaccine induced neutralizing antibodies and monoclonal therapeutics have progressively
134 lost neutralization potency against emerging variants of concern (VOC)(5, 22). Yet unlike previous
135 VOCs, Omicron possesses more than 40 mutations, including 29 in the Spike protein, that, to
136 date, represents the most profound escape from natural and vaccine induced neutralizing
137 antibody activity. This loss of neutralization, coupled to enhanced ACE2-binding, accounts for the
138 remarkable rise in transmission events globally. However, as a second line defense, following
139 infection, both direct and indirect cellular mechanisms contribute to pathogen control and
140 clearance. Specifically, T cells may directly recognize and kill infected cells (9). Additionally,
141 antibodies able to leverage innate immune activity can both drive the rapid elimination of viral
142 particles as well as deploy the cytotoxic power of the immune system to kill infected cells(19).
143 While emerging data point to persistent COVID-19 vaccine induced T cell recognition of Omicron
144 (4), it was unclear whether vaccine induced antibodies continue to leverage Fc-activity against
145 this novel VOC.

146 Here we observed a more pronounced loss of Omicron-RBD compared to Omicron-Spike
147 isotype/subclass and FcR binding was observed across vaccine platforms, likely linked to the
148 preferential incorporation of mutations in the S1 domain of the SARS-CoV-2 spike. However,
149 unlike neutralizing antibodies, that must target a limited number of regions on the Spike, involved
150 in attachment, positioning of the RBD, or fusion, antibodies that mediate Fc-activity can likely
151 bind across the entire antigenic surface. Fc-activity solely requires formation of immune
152 complexes and arrangements of antibodies with Fc-domains that are accessible to local immune
153 cells. The persistence of Omicron-IgG binding to the Spike antigen across the mRNA and
154 inactivated vaccine platforms suggests that vaccine induced antibodies may continue to opsonize
155 the virus and virally infected cells even after infection with of Omicron. Thus, while neutralizing

156 antibodies are likely to be key to blocking transmission, non-neutralizing antibodies able to
157 leverage Fc-biology may contribute to persistent disease attenuation.

158 While the three vaccines maintained more robust binding to Omicron Spike specific
159 FcγR2a, a selective loss of FcγR2b and FcγR3b was observed across the platforms. FcγR2b is the
160 sole low-affinity inhibitory receptor in humans, likely involved in attenuated inflammatory
161 activity (20). Likewise, FcγR3b is solely expressed on neutrophils, likely critical for rapid
162 opsonophagocytic clearance of opsonized viral particles (20). While continued binding to FcγR2a
163 and FcγR3a may lead to continued clearance of particles and killing of infected cells, the loss of
164 FcγR2b and FcγR3b may result in a more inflammatory response, that may translate to symptoms,
165 but may still attenuate severity and death. Likewise, emerging epidemiological reports suggest
166 that Omicron infection, while less severe, causes mild to moderate symptomatic infection(23,
167 24). However, real-world comparisons of symptom severity across vaccine platforms are needed
168 to provide enhanced resolution of the roles of individuals FcγRs in attenuating disease.

169 While many developed countries have begun aggressive boosting campaigns, the majority
170 of the world, where many variants may evolve, remains incompletely vaccinated. Thus,
171 understanding the ability of distinct vaccines to drive immunity to Omicron is urgently needed.
172 Moreover, defining the immunological mechanisms that contribute to disease attenuation, in the
173 absence of neutralization, may provide key insights to guide effective pan VOC-vaccine design
174 and boosting campaigns to help control the global COVID-19 pandemic. Here we demonstrate
175 the persistence of Omicron Spike-, but reduced RBD-, specific binding and Fc-activating potential
176 across vaccine platforms, providing some initial insights on persisting mechanisms that may
177 contribute to disease attenuation despite the significant loss of neutralization to this novel SARS-
178 CoV2 variant of concern.

179

180

181

182

183

184

185 **Competing interests**

186 G.A. is a founder and equity holder of Seromyx Systems, a company developing a platform
187 technology that describes the antibody immune response. G.A. is an employee and equity holder
188 of Leyden Labs, a company developing pandemic prevention therapeutics. G.A.'s interests were
189 reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in
190 accordance with their conflict of interest policies. All other authors have declared that no
191 conflicts of interest exist.

192

193 **Data Availability Statement**

194 All data produced in the present work are contained in the manuscript

195

196 **Acknowledgments**

197 We thank Nancy Zimmerman, Mark and Lisa Schwartz, an anonymous donor (financial support),
198 Terry and Susan Ragon, and the SAMANA Kay MGH Research Scholars award for their support.
199 We acknowledge support from the Ragon Institute of MGH, MIT, and Harvard, the Massachusetts
200 Consortium on Pathogen Readiness (MassCPR) and the Musk foundation. This study was funded
201 by the NIH (3R37AI080289-11S1, R01AI146785, U19AI42790-01, U19AI135995-02, U19AI42790-
202 01, 1U01CA260476-01, CIVIC75N93019C00052 and The Gates Foundation Global Health Vaccine
203 Accelerator Platform (OPP1146996 and INV-001650). Work in the Medina Laboratory was based
204 on protocols and the study set-up established in part with the support from FONDECYT 1212023
205 grant from the Agencia Nacional de Investigación y Desarrollo (ANID) of Chile, the FLUOMICS
206 Consortium (NIH-NIAD grant U19AI135972) and the Center for Research on Influenza
207 Pathogenesis (CRIP), an NIAID Center of Excellence for Influenza Research and Surveillance
208 (CEIRS, contract # HHSN272201400008C). We greatly appreciate the outstanding technical work
209 of Erick Salinas, Estefany Poblete and Andres Muñoz. MJA and ES conducted this work as part of
210 their Ph.D. Thesis, Programa de Doctorado en Ciencias Biológicas mención Genética Molecular y
211 Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile. This work
212 used samples from the phase 1 mRNA-1273 study (NCT04283461; DOI:
213 10.1056/NEJMoa2022483). The mRNA-1273 phase 1 study was sponsored and primarily funded

214 by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health
215 (NIH), Bethesda, MD. This trial has been funded in part with federal funds from the NIAID under
216 grant awards UM1AI148373, to Kaiser Washington; UM1AI148576, UM1AI148684, and NIH P51
217 OD011132, to Emory University; NIH AID AI149644, and contract award HHSN272201500002C,
218 to Emmes. Funding for the manufacture of mRNA-1273 phase 1 material was provided by the
219 Coalition for Epidemic Preparedness Innovation.

220

221 **Methods**

222 **Study population**

223 To compare antibody responses elicited by the different vaccines, samples were obtained at peak
224 immunogenicity timepoints from individuals who were vaccinated with the full dose regimen
225 recommended by the respective manufacturer. As part of a phase 1 clinical trial in the US
226 (NCT04283461) individuals received two doses 100 µg mRNA-1273 at days 0 and 28 and samples
227 taken two weeks after the second dose. BNT162b2 vaccinated individuals received 30 µg
228 BNT162b2 at days 0 and 21 and samples were taken two weeks after the second dose. Individuals
229 from Chile received two doses 600U CoronaVac four weeks apart and samples were taken two
230 weeks after the second dose. For the CoronaVac study informed written consent was obtained
231 under protocol 200829003 which was reviewed and approved by the Scientific Ethics Committee
232 at Pontificia Universidad Católica de Chile (PUC). This study was overseen and approved by the
233 MassGeneral Institutional Review Board (IRB #2020P00955 and #2021P002628).

234 **Antigens**

235 Receptor-binding domain antigens for the wildtype (Wuhan), alpha (B.1.1.7), beta (B.1.351), and
236 delta (B.1.617.2) VOCs were obtained from Sino-Biologicals. Omicron RBD was generously
237 provided by Moderna Inc. Stabilized (hexa-pro) spike of D614G or respective variants was
238 produced in HEK293 cells.

239

240 **IgG subclass, isotype and FcγR binding**

241 Antigen specific antibody subclass and isotypes, and FcγR binding was analyzed by Luminex
242 multiplexing. The antigens were coupled to magnetic Luminex beads (Luminex Corp, TX, USA) by

243 carbodiimide-NHS ester-coupling with an individual region per antigen. Coupled beads were
244 incubated with different plasma dilutions (1:100 for IgG2, IgG3, IgG4, IgM and IgA1, 1:500 for
245 IgG1 and 1:1,000 for FcγR probing) for 2 hours at room temperature in 384 well plates (Greiner
246 Bio-One, Germany). Unbound antibodies were washed away and subclasses, isotypes were
247 detected with a respective PE-conjugated antibody (anti-human IgG1, IgG2, IgG3, IgG4, IgM or
248 IgA1 all SouthernBiotech, AL, USA) at a 1:100 dilution. For the analysis of FcγR binding PE-
249 Streptavidin (Agilent Technologies, CA, USA) was coupled to recombinant and biotinylated
250 human FcγR2a, FcγR2b, FcγR3a, or FcγR3b protein. Coupled FcγR were used as a secondary probe
251 at a 1:1000 dilution. After 1 h incubation, excessive secondary reagent was washed away and the
252 relative antibody concentration per antigen determined on an IQue analyzer (IntelliCyt).

253

254 **Statistical analysis**


255 If not stated otherwise, we assumed non-normal distributions and plots were generated and
256 statistical differences between two groups were calculated in Graph Pad Prism V.8. A Kruskal-
257 Wallis test with a Benjamini-Hochberg post-test correcting for multiple comparisons was used to
258 test for statistical differences between wildtype variant and omicron titer.

259

260 References

- 261 1. S. A. Plotkin, Vaccines: correlates of vaccine-induced immunity. *Clin Infect Dis* **47**, 401-
262 409 (2008).
- 263 2. L. L. Lu, T. J. Suscovich, S. M. Fortune, G. Alter, Beyond binding: antibody effector
264 functions in infectious diseases. *Nat Rev Immunol* **18**, 46-61 (2018).
- 265 3. D. S. Khoury *et al.*, Neutralizing antibody levels are highly predictive of immune
266 protection from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021).
- 267 4. S. F. Ahmed, A. A. Quadeer, M. R. McKay, SARS-CoV-2 T cell responses are expected to
268 remain robust against Omicron. *bioRxiv*, 2021.2012.2012.472315 (2021).
- 269 5. L. A. VanBlargan *et al.*, An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes
270 neutralization by several therapeutic monoclonal antibodies. *bioRxiv*,
271 2021.2012.2015.472828 (2021).
- 272 6. T. Zohar *et al.*, Compromised Humoral Functional Evolution Tracks with SARS-CoV-2
273 Mortality. *Cell* **183**, 1508-1519 e1512 (2020).
- 274 7. C. E. Z. Chan *et al.*, The Fc-mediated effector functions of a potent SARS-CoV-2
275 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are
276 essential for the optimal therapeutic efficacy of the antibody. *PLoS One* **16**, e0253487
277 (2021).
- 278 8. M. J. Gorman *et al.*, Fab and Fc contribute to maximal protection against SARS-CoV-2
279 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. *Cell Rep Med*,
280 100405 (2021).
- 281 9. A. T. Tan *et al.*, Early induction of functional SARS-CoV-2-specific T cells associates with
282 rapid viral clearance and mild disease in COVID-19 patients. *Cell Rep* **34**, 108728 (2021).
- 283 10. S. Jegaskanda, H. A. Vandervan, A. K. Wheatley, S. J. Kent, Fc or not Fc; that is the
284 question: Antibody Fc-receptor interactions are key to universal influenza vaccine
285 design. *Hum Vaccin Immunother* **13**, 1-9 (2017).
- 286 11. D. J. DiLillo, P. Palese, P. C. Wilson, J. V. Ravetch, Broadly neutralizing anti-influenza
287 antibodies require Fc receptor engagement for in vivo protection. *J Clin Invest* **126**, 605-
288 610 (2016).
- 289 12. B. M. Gunn *et al.*, A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated
290 Protection against Ebola Virus. *Cell Host Microbe* **24**, 221-233 e225 (2018).
- 291 13. L. Zeitlin *et al.*, Enhanced potency of a fucose-free monoclonal antibody being
292 developed as an Ebola virus immunoprotectant. *Proc Natl Acad Sci U S A* **108**, 20690-
293 20694 (2011).
- 294 14. S. Bournazos *et al.*, Broadly neutralizing anti-HIV-1 antibodies require Fc effector
295 functions for in vivo activity. *Cell* **158**, 1243-1253 (2014).
- 296 15. L. R. Baden *et al.*, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J*
297 *Med* **384**, 403-416 (2021).
- 298 16. F. P. Polack *et al.*, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J*
299 *Med* **383**, 2603-2615 (2020).
- 300 17. R. Palacios *et al.*, Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to
301 Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed

- 302 COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured
303 summary of a study protocol for a randomised controlled trial. *Trials* **21**, 853 (2020).
- 304 18. K. M. Hastie *et al.*, Defining variant-resistant epitopes targeted by SARS-CoV-2
305 antibodies: A global consortium study. *Science* **374**, 472-478 (2021).
- 306 19. G. Vidarsson, G. Dekkers, T. Rispens, IgG subclasses and allotypes: from structure to
307 effector functions. *Front Immunol* **5**, 520 (2014).
- 308 20. P. Bruhns, F. Jonsson, Mouse and human FcR effector functions. *Immunol Rev* **268**, 25-
309 51 (2015).
- 310 21. J. Zahradnik *et al.*, SARS-CoV-2 variant prediction and antiviral drug design are enabled
311 by RBD in vitro evolution. *Nat Microbiol* **6**, 1188-1198 (2021).
- 312 22. D. Planas *et al.*, Considerable escape of SARS-CoV-2 variant Omicron to antibody
313 neutralization. *bioRxiv*, 2021.2012.2014.472630 (2021).
- 314 23. N. Wolter *et al.*, Early assessment of the clinical severity of the SARS-CoV-2 Omicron
315 variant in South Africa. *medRxiv*, 2021.2012.2021.21268116 (2021).
- 316 24. A. Sheikh, S. Kerr, M. Woolhouse, J. McMenamin, C. Robertson, Severity of Omicron
317 variant of concern and vaccine effectiveness against symptomatic disease: national
318 cohort with nested test negative design study in Scotland. *Research output: Working
319 paper › Preprint*, (2021).
- 320
- 321




322

323 **Figure 1: Vaccine induced antibody binding to different SARS-CoV-2 variants of concern.**

324 Individuals either received the full dose regimen of the BNT162b2(n = 11), mRNA-1273(n=14), or
325 the aluminum adjuvanted inactivated particle vaccine CoronaVac (n=13). Samples were taken at
326 peak immunogenicity 2 weeks after the last dose. IgM, IgA1 and IgG1 binding titers to D614G
327 (WT), Alpha (B.1.117), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B1.529) variants of concern
328 receptor binding domain (A) or full Spike (B) were measured by Luminex. Background corrected
329 data is shown and negative values were set to 100 for graphing purposes. A Kruskal-Wallis test
330 with a Benjamini-Hochberg post-test correcting for multiple comparisons was used to test for
331 statistical differences between wildtype variant and omicron titer. P-values for significant
332 different features are shown above and fold change reduction of omicron titer compared to
333 wildtype below each dataset.

334



335

336 **Figure 2: Vaccine induced Fcγ-receptor binding antibody profiles across SARS-CoV-2 variants of**

337 **concern.** Individuals either received the full dose regimen of the BNT162b2(n = 11), mRNA-1273(

338 n=14), or the aluminum adjuvanted inactivated particle vaccine CoronaVac (n=13). Samples were

339 profiled at peak immunogenicity 2 weeks after the last dose. Binding to FcγR2a, FcγR2b, FcγR3a

340 and FcγR3b of D614G (WT), Alpha (B1.117), Beta (B1.351), Delta (B.1.617.2), and Omicron

341 (B1.529) variant of concern receptor binding domain (A) or full Spike (B) specific antibodies were

342 determined by Luminex. Background corrected data is shown and negative values were set to

343 100 for graphing purposes. A Kruskal-Wallis test with a Benjamini-Hochberg post-test correcting

344 for multiple comparisons was used to test for statistical differences between wildtype variant

345 and omicron titer. P-values for significant different features are shown above and fold change

346 reduction of omicron titer compared to wildtype below each dataset.